Back to Directory Maggie Albano Email malbano@fhi360.org Phone 202-464-3753 Institution FHI 360 Address IMPAACT Operations Center FHI 360 359 Blackwell Street Suite 200 Durham, NC 27701 USA Request an Update Affiliated Studies IMPAACT 2034: Phase 1 Study of the Pharmacokinetics, Safety, and Acceptability of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children with Rifampicin-Resistant Tuberculosis DAIDS Number 38754 Research Area Tuberculosis Study Status Enrolling IMPAACT 2046: UPLIFT Study DAIDS Number 39171 Research Area Brain and Mental Health Study Status Enrolling IMPAACT 2041: Phase I/II Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women with Hepatitis C with and without HIV DAIDS Number 39052 Research Area Therapeutics Study Status Open to Accrual IMPAACT 2016: Evaluating a Group-Based Intervention to Improve Mental Health and ART Adherence Among Youth Living with HIV in Low Resource Settings DAIDS Number 38506 Research Area Brain and Mental Health Study Status Participants Off Study and Primary Analysis Completed Show All
IMPAACT 2034: Phase 1 Study of the Pharmacokinetics, Safety, and Acceptability of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children with Rifampicin-Resistant Tuberculosis DAIDS Number 38754 Research Area Tuberculosis Study Status Enrolling
IMPAACT 2046: UPLIFT Study DAIDS Number 39171 Research Area Brain and Mental Health Study Status Enrolling
IMPAACT 2041: Phase I/II Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women with Hepatitis C with and without HIV DAIDS Number 39052 Research Area Therapeutics Study Status Open to Accrual
IMPAACT 2016: Evaluating a Group-Based Intervention to Improve Mental Health and ART Adherence Among Youth Living with HIV in Low Resource Settings DAIDS Number 38506 Research Area Brain and Mental Health Study Status Participants Off Study and Primary Analysis Completed